facebook Twitter Instagram YouTube
Press Releases
Press Releases

September 29th, 2017
RUCONEST® provided clinically meaningful relief of symptoms in children with hereditary angioedema

September 14th, 2017
KalVista Pharmaceuticals Reports Fiscal First Quarter Results

September 11th, 2017
Shire’s Investigational Subcutaneous C1 esterase inhibitor (C1 INH [Human]) Liquid for Injection (SHP616) Significantly Reduces Hereditary Angioedema Monthly Attack Rate Versus Placebo in a Phase 3 Pivotal Trial

September 11th, 2017
Pharming announces conclusion of FDA End of Phase 2 interactions on RUCONEST® for Prophylaxis of HAE

September 5th, 2017
BioCryst Announces Positive Results from its APeX-1 Phase 2 Trial in HAE

July 26th, 2017
Pharming announces publication of RUCONEST® prophylactic data in The Lancet

July 23rd, 2017
FDA Approves HAEGARDA® King Of Prussia, PA

June 22nd, 2017
FDA Approves First Subcutaneous C1 Esterase Inhibitor To Treat Rare Genetic Disease

May 24th, 2017
Attune Pharmaceuticals Announces Positive Data from Recent Pre-Clinical Studies for ATN-249, an Oral Plasma Kallikrein Inhibitor for the Treatment of HAE at C1-INH Deficiency Workshop

May 24th, 2017
Shire's Investigational Treatment Lanadelumab Reduces Hereditary Angioedema Monthly Attack Rate by 87% Versus Placebo in Phase 3 26-week Pivotal Trial

April 13th, 2017
BioCryst Expands Development of BCX7353 to Explore Treatment of Acute HAE Attacks

March 23rd, 2017
New England Journal of Medicine Publishes Pivotal Phase III Data for CSL Behring’s Subcutaneous C1-Esterase Inhibitor in HAE Patients

Michelle Cuevas
Press Contact